Condition: Neurogenic Detrusor Overactivity · Spinal Cord Injuries · Sponsor: Cyllene Therapeutics
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.
This description comes directly from the study's public registry record.
Sandrine Zourbas, Ph.D. · 33 (0)6 25 62 28 02 · szourbas@eg427.com
Cornelia Haag-Molkenteller, MD · Cornelia@eg427.com
Always discuss trial participation with your own doctor first.
| Rancho Los Amigos National Rehabilitation Center | Downey, California, United States | Recruiting |
| University of Michigan Rogel Cancer Center | Ann Arbor, Michigan, United States | Withdrawn |
| Sidney Kimmel Medical College | Philadelphia, Pennsylvania, United States | Recruiting |
| UTHealth Houston / TIRR Memorial Hermann | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06596291